NCT07274020Not yet recruitingPhase 3
Long-Term Safety and Efficacy of Moxifloxacin in Bronchiectasis Patients
Effectiveness and Safety of Long-Term Intermittent Moxifloxacin Eradication Therapy in Non-Cystic Fibrosis Bronchiectasis: A 12-Month Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 10 Dec 2025
Brief summary (registry, in English)
Bronchiectasis is a chronic respiratory disease characterized by recurrent infections, inflammation, and progressive lung damage. Frequent exacerbations are associated with increased morbidity, accelerated lung function decline, and reduced quality of life. Preventing exacerbations is a key therapeutic goal. Moxifloxacin, a fluoroquinolone antibiotic with broad-spectrum activity, may play a role in intermittent eradication therapy to reduce bacterial load, achieve microbiological clearance, and minimize exacerbation frequency. This randomized controlled trial will evaluate the effectiveness and safety of long-term intermittent moxifloxacin therapy compared with standard care in patients with non-cystic fibrosis bronchiectasis.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- First submitted
- 1 Oct 2025
- Start date
- 1 Dec 2025
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- Assiut University
- Diseases
- Cystic fibrosis
- NCT number
- NCT07274020
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 140
- From 1 Dec 2025 to the primary completion date, 1 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known hypersensitivity or contraindication to fluoroquinolones (including moxifloxacin).
Lab values
- Severe hepatic impairment or severe renal impairment (eGFR \<30 mL/min/1.73 m²).
- History of significant QT prolongation, arrhythmia, or concurrent use of QT-prolonging drugs.
Other
- Diagnosis of cystic fibrosis-related bronchiectasis.
- Pregnancy or breastfeeding.
- Use of long-term suppressive antibiotics for bronchiectasis in the past 3 months.
Who the study is looking for
- Adults ≥18 years of age.
- Confirmed diagnosis of non-cystic fibrosis bronchiectasis by high-resolution CT (HRCT).
- History of ≥2 bronchiectasis exacerbations in the previous 12 months.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Assiut University hospital Coordinator of this site? Confirm its status | Asyut | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.